abstract |
The use of a compound of Formula (I): whereinn for example: X and Y are independently selected from: oxygen, sulphur and (-CRaRb-)n; wherein: n is an integer of from 1 to 4 and Ra and Rb are each independently selected from hydrogen, C1-6alkyl, C1-6alkoxy, halo, hydroxy, C1-6alkanoyloxy, C3-12cycloalkyl and optionally substituted phenyl or Ra and Rb together form a C5-12spirocycloalkyl or a carbonyl; R1 and R3 are independently selected from (a) optionally substituted phenyl or phenoxy; (b) optionally substituted naphth-1-yl or naphth-2-yl; (c) arylC1-6alkyl; (d) C1-20alkyl or C1-20alkenyl; and (e) adamantyl or a C3-12cycloalkyl R2 is hydrogen, a C1-8alkyl or benzyl; or pharmaceutically acceptable salt, pro-drug or solvate thereof as DGAT inhibitors and in the manufacture of a medicament for the treatment of type II diabetes and/or obesity. |